SEC
Filings

SEC Filings

SEC Filings

Filing date	Form	Description	Filing Group	View
Apr 06, 2017	EFFECT	EFFECT	Other	View HTML 9999999995-17-000756.pdf 9999999995-17-000756.rtf 9999999995-17-000756.xls
Sep 27, 2018	EFFECT	EFFECT	Other	View HTML 9999999995-18-002478.pdf 9999999995-18-002478.rtf 9999999995-18-002478.xls
Apr 12, 2019	EFFECT	EFFECT	Other	View HTML 9999999995-19-000701.pdf 9999999995-19-000701.rtf
Jan 11, 2021	EFFECT	EFFECT	Other	View HTML 9999999995-21-000116.pdf 9999999995-21-000116.rtf 9999999995-21-000116.xls
Aug 10, 2017	NT 10-Q	Notification that form type 10-Q will be submitted late	Quarterly Filings	View HTML 0001193125-17-253789.pdf 0001193125-17-253789.rtf 0001193125-17-253789.xls
Nov 26, 2008	POS AM	Post-effective amendment to an S-Type filing	Registration Statements	View HTML 0001104659-08-073455.pdf 0001104659-08-073455.rtf 0001104659-08-073455.xls
Feb 09, 2009	POS AM	Post-effective amendment to an S-Type filing	Registration Statements	View HTML 0001104659-09-007702.pdf 0001104659-09-007702.rtf 0001104659-09-007702.xls
Sep 28, 2018	POS EX	POS EX	Registration Statements	View HTML 0001193125-18-286447.pdf 0001193125-18-286447.rtf 0001193125-18-286447.xls
Feb 09, 2007	PRE 14A	A preliminary proxy statement providing notification matters to be brought to a vote	Proxy Filings	View HTML 0001144204-07-006362.pdf 0001144204-07-006362.rtf 0001144204-07-006362.xls
Jul 13, 2007	PRE 14A	A preliminary proxy statement providing notification matters to be brought to a vote	Proxy Filings	View HTML 0001144204-07-036403.pdf 0001144204-07-036403.rtf 0001144204-07-036403.xls

Data provided by Kaleidoscope.

Investor Contact

Richard Eisenstadt
Chief Financial Officer

Email: reisenstadt@altimmune.com

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

© 2024 Altimmune. All rights reserved.